Wire · opportunities
Roche, Eli Lilly get FDA nod for new Alzheimer's blood test
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 August 2026 · Fusion42 review
The FDA approved a new blood test developed by Roche and Eli Lilly for detecting amyloid pathology linked to Alzheimer's in adults 55 and older with cognitive decline symptoms, aiming to provide easier early diagnosis compared to traditional PET or CSF tests.
This Wire brief sits within Fusion42's coverage of Digital Health, and 2 sources have reported it between 24 Aug 2026 and 25 Aug 2026.
◆ ◆ The Wire takeaway
You now have a path to enter the Alzheimer’s diagnostics market with a standardised FDA-cleared blood test, challenging the PET and CSF tests that limited early diagnosis outside specialised centres. Start building partnerships with diagnostic labs and clinicians who need scalable tools for cognitive health screening.
◆ Coverage
2 sources · first reported 24 Aug 2026 · latest 25 Aug 2026
◆ Related on Wire
◆ Topics